Skip to main content

Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis

 

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic

 

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings

 

To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).

§  Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.

§  A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.

§  A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.

§  A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.

§  An analysis of the varied microbiome-focused initiatives of big pharma players.

§  An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.

§  An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.

§  An analysis of the investments made at various stages of development in start-ups / small-sized companies.

§  An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.

§  An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.

§  An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

segments:

§  Type of Therapy (Tx)

§  Prescription Drug

§  Prebiotics

§  Probiotics

       

§  Type of Molecule (Tx)

§  Small Molecules

§  Biologics

 

§  Target Indication (Tx+Dx)

§  Acne Vulgaris

§  Atopic Dermatitis

§  Clostridium difficile Infection

§  Colorectal Cancer

§  Crohn’s Disease

§  Diabetes

§  Irritable Bowel Syndrome

§  Lactose Intolerance

§  Lung Cancer

§  Nonalcoholic steatohepatitis (NASH)

§  Obesity

§  Ulcerative colitis

 

To request a sample copy / brochure of this report, please visit this- https://www.rootsanalysis.com/reports/281/request-sample.html

 

§  Therapeutic Area (Tx+Dx)

§  Autoimmune Disorders

§  Dental Disorders

§  Digestive and Gastrointestinal Disorders

§  Dermatological Disorders

§  Infectious Disease

§  Metabolic Disorders

§  Oncology

§  Others

 

§  Key Geographical Regions (Tx+Dx)

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 

Key companies covered in the report

§  4D Pharma

§  Armata Pharmaceuticals

§  Evelo Biosciences

§  Rebiotix (Acquired by Ferring Pharmaceuticals)

§  Seres Therapeutics

§  Vedanta Biosciences

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more